Methylomics of pediatric traumatic brain injury and neurobehavioral recovery
Project Number1R01NS135492-01A1
Former Number1R01NS135492-01
Contact PI/Project LeaderTREBLE-BARNA, AMERY
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
PROJECT SUMMARY
Traumatic brain injury (TBI) is the leading cause of acquired disability in children. The evidence available to
guide TBI management is disproportionately low relative to its medical and societal burden. Recovery from TBI
is determined by the interaction of a multitude of dynamic biological, psychosocial, and therapeutic factors.
DNA methylation (DNAm; the methylome) is a major epigenetic regulator of gene expression that responds
dynamically to an individual’s internal (e.g., tissue insult) and external (e.g., psychosocial adversity)
environment. Initial preclinical and adult clinical studies show differential DNAm both acutely and months after
TBI; however, little is known regarding pediatric TBI. Because the methylome is dynamic over time and
responsive to both internal and external factors associated with TBI recovery, we hypothesize that the
methylome confers risk or protective effects on long-term neurobehavioral recovery through the regulation of
genes involved in the brain’s response to TBI. Therefore, interrogation of the methylome could reveal critical
information about the biologic complexity underlying recovery, with significant potential for improving future
clinical management of pediatric TBI. To further interrogate the methylome as an untapped source of biologic
complexity underlying recovery from pediatric TBI, we will generate methylome-wide DNAm data from an
ongoing longitudinal study of children aged 3-18 years with complicated mild to severe TBI or orthopedic injury
(OI; comparison group). Our two-tiered analytic approach will involve: Tier 1. Comprehensive examination of
brain derived-neurotrophic factor (BDNF) DNAm (~55 DNAm sites), grounded in our strong preliminary data;
and Tier 2. Unbiased discovery-based analysis of the entire methylome (>935,000 sites), revealing the most
significant methylomic signals for future targeted biomarker research. Both Tiers will be examined within each
of the following Specific Aims: (1) Determine the association between pediatric TBI and acute DNAm; (2)
Identify associations between acute DNAm and long-term neurobehavioral outcomes; (3) Identify associations
between acute DNAm and disparities in neurobehavioral outcomes as a function of psychosocial adversity;
and (4) Explore associations between longitudinal DNAm and neurobehavioral recovery. Exemplifying rigor
and reproducibility, our approach includes analysis of a discovery cohort (235 TBI, 179 OI) followed by
replication in an independent cohort (105 TBI, 105 OI). Finally, we will conduct clinical feasibility testing to
ensure that only the most rigorous, reproducible, and clinically translatable findings advance for further
scientific inquiry. The overall impact of this work will be to advance the field of pediatric TBI towards precision
medicine and health equity through an improved understanding of the biologic complexity underlying recovery
and its intersection with psychosocial adversity; revealing biologic signatures of risk for poor recovery; and
identification of DNAm sites with potential for clinical translation as methylomic biomarkers that could
revolutionize TBI management.
Public Health Relevance Statement
PROJECT NARRATIVE
The many biological and environmental factors influencing recovery from pediatric traumatic brain injury (TBI)
are poorly understood, resulting in inaccurate prediction of outcomes and few effective treatments. This project
will investigate DNA methylation/the “methylome”, a major epigenetic regulator of gene expression, as an
untapped source of biologic complexity underlying recovery from pediatric TBI. The overall impact of this work
will be to improve our understanding of the biologic complexity underlying pediatric TBI recovery, reveal
biologic signatures of risk for poor recovery, and identify potential methylomic biomarkers that could
revolutionize TBI management.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
004514360
UEI
MKAGLD59JRL1
Project Start Date
15-May-2024
Project End Date
30-April-2029
Budget Start Date
15-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$615,627
Direct Costs
$397,115
Indirect Costs
$218,512
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$615,627
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS135492-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS135492-01A1
Patents
No Patents information available for 1R01NS135492-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS135492-01A1
Clinical Studies
No Clinical Studies information available for 1R01NS135492-01A1
News and More
Related News Releases
No news release information available for 1R01NS135492-01A1
History
No Historical information available for 1R01NS135492-01A1
Similar Projects
No Similar Projects information available for 1R01NS135492-01A1